, Volume 26, Issue 6, pp 363–376 | Cite as

‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas

Still a Viable Strategy?
Current Opinion


Observation until the development of symptoms, or ‘watch and wait’, has long been a proposed management technique for patients with indolent lymphomas. However, investigators have found that there may be differences in outcomes for various patient groups according to histopathology, clinical features of the disease, biologic factors as yet to be fully recognized, and type of initial therapy offered. Recently, investigators from the UK National Cancer Research Institute reported that progression-free results were significantly improved when asymptomatic patients with indolent follicular lymphomas received initial therapy with single-agent rituximab rather than when they underwent observation alone. These results were further improved when they received maintenance rituximab. Time to chemotherapy was also longer when these patients received initial therapy with rituximab, thereby delaying the need for such treatment. However, overall survival rates for patients who received rituximab as initial therapy were similar to those for patients who underwent initial ‘watch and wait’. Future studies should concentrate on risks of such management, including cost effectiveness of such treatments and development of resistance to subsequent therapies.



No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this article.


  1. 1.
    Portlock C, Rosenberg S. No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 1979; 90: 10–3PubMedCrossRefGoogle Scholar
  2. 2.
    Horning S, Rosenberg S. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311: 1471–5PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson T, DeVita V, Simon R, et al. Malignant lymphoma. II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–21PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson T, Bender R, Fisher R, et al. Combination chemotherapy in non-Hodgkin’s lymphoma: results of long-term follow-up. Cancer Treat Rep 1977; 61: 1057–66PubMedGoogle Scholar
  5. 5.
    Rosenberg S. Non-Hodgkin’s lymphoma: selection of treatment on the basis of histologic type. N Engl J Med 1979; 30: 924–8CrossRefGoogle Scholar
  6. 6.
    Glatstein E, Donaldson S, Rosenberg S, et al. Combined modality therapy in malignant lymphomas. Cancer Treat Rep 1977; 61: 1199–207Google Scholar
  7. 7.
    Soubeyran P, Egbahli H, Trojani F, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? Astudy of 43 consecutive patientsina single center. Ann Oncol 1996; 7: 713–8PubMedCrossRefGoogle Scholar
  8. 8.
    Advani R, Rosenberg S, Horning S. Stage I and II follicular non-Hodgkin’ lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–9PubMedCrossRefGoogle Scholar
  9. 9.
    Gospadarowicz M, Bush R, Brown T, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984; 10: 489–97CrossRefGoogle Scholar
  10. 10.
    Pendlebury S, Awadi M, Askley S, et al. Radiotherapy results in early stage low grade nodal non-Hodgkin’s lymphoma. Radiother Oncol 1985; 36: 167–71CrossRefGoogle Scholar
  11. 11.
    Vaughan Hudson B, Vaughan Hudson G, MacLennan K, et al. Clinical stage I non-Hodgkin’s lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69: 1088–93PubMedCrossRefGoogle Scholar
  12. 12.
    Denham J, Denham E, Dear K, et al. The follicular non-Hodgkin’s lymphomas — I: the possibility of cure. Eur J Cancer 1996; 32A: 470–9PubMedCrossRefGoogle Scholar
  13. 13.
    MacManus M, Hoppe R. Is radiotherapy curative for stage I and IIlow-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282–90Google Scholar
  14. 14.
    Wilder R, Jones D, Tucker S, et al. Long-term results with radiotherapy for stage I–II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219–27PubMedCrossRefGoogle Scholar
  15. 15.
    Guadagnolo B, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64: 928–34PubMedCrossRefGoogle Scholar
  16. 16.
    Ardeshna K, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 2003; 362: 516–22PubMedCrossRefGoogle Scholar
  17. 17.
    Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol 1997; 15: 1110–7PubMedGoogle Scholar
  18. 18.
    Coiffier B, Bastion Y, Berger F, et al. Prognostic factors in follicular lymphoma. Semin Oncol 1993; 86: 1460–3Google Scholar
  19. 19.
    Young R, Longo D, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality. Semin Hematol 1988; 25 Suppl. 2: 11–6PubMedGoogle Scholar
  20. 20.
    Ardeshna K, Smith P, Qian W, et al. An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): a preliminary analysis [abstract no.6]. Blood 2010; 116: 5Google Scholar
  21. 21.
    Ardeshna K, Qian W, Stephens R, et al. Preliminary results of quality of life (QoL) analyses from the intergroup phase III randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma [abstract no. 019]. Ann Oncol 2011; 22 Suppl. 4: iv88Google Scholar
  22. 22.
    Hainsworth J, Litchy S, Shaffer D, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non Hodgkin’s lymphoma — a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–95PubMedCrossRefGoogle Scholar
  23. 23.
    Martinelli G, Schmitz S, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480–4PubMedCrossRefGoogle Scholar
  24. 24.
    Gordon L, Grow W, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096–102CrossRefGoogle Scholar
  25. 25.
    Kahl B, Hong F, Williams M, et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma (late-breaking abstract). Proceedings of the American Society of Hematology, Plenary Session; 2011 Dec 6; San Diego (CA)Google Scholar
  26. 26.
    Taverna C, Bassi S, Hitz F, et al. Rituximab treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized SAKK 35/03 [abstract no. 1802]. Blood 2010; 116: 752Google Scholar
  27. 27.
    Berinstein N, Grillo-Lopez A, White C, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998; 9: 995–1001PubMedCrossRefGoogle Scholar
  28. 28.
    Pettengell E, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract no. 8005]. J Clin Oncol 2010; 28 Suppl. 15s: 574sGoogle Scholar
  29. 29.
    Foa R, Di Rocco A, van Hazel G, et al. Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard and rapid infusion: updated results from the phase IIIb MAXIMA study [abstract no. 3945]. Blood 2010; 116: 1608Google Scholar
  30. 30.
    Hochster H, Weller E, Gascoyne R, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival inadvanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009; 27: 1607–14PubMedCrossRefGoogle Scholar
  31. 31.
    van Oers M, Van Glabbeke M, Giurgeo L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853–8PubMedCrossRefGoogle Scholar
  32. 32.
    Salles G, Seymour J, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011; 377: 42–51PubMedCrossRefGoogle Scholar
  33. 33.
    Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. New Engl J Med 1993; 329: 1608–14PubMedCrossRefGoogle Scholar
  34. 34.
    Steward W, Crowther D, McWilliam L, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’s lymphoma. Cancer 1988; 61: 441–7PubMedCrossRefGoogle Scholar
  35. 35.
    Romaguera J, McLaughlin P, North L, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma. Cancer 1991; 61: 441–7Google Scholar
  36. 36.
    Soubeyran P, Eghbali H, Bonichon F, et al. Low-grade follicular lymphomas: analysisof prognosis ina series of 281 patients. Eur J Cancer 1991; 27: 1606–13PubMedCrossRefGoogle Scholar
  37. 37.
    Bastion Y, Berger F, Bryon P, et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2 Suppl. 2: 123–34PubMedCrossRefGoogle Scholar
  38. 38.
    Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Am J Med 1991; 114: 855–60Google Scholar
  39. 39.
    Leonard R, Hayward R, Prescott R, et al. The identification of discrete prognostic groups in low-grade non-Hodgkin’s lymphoma: The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1992; 2: 655–62Google Scholar
  40. 40.
    Horning S. Natural history of and therapy for the indolent non-Hodgkin’ lymphomas. Semin Oncol 1993; 20: 75–80PubMedGoogle Scholar
  41. 41.
    Cameron D, Leonard R, Mao J, et al. Identification of prognostic groups in follicular lymphoma. Leuk Lymphoma 1993; 10: 89–99PubMedCrossRefGoogle Scholar
  42. 42.
    Gospodarowicz M, Bush R, Brown T, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1994; 10: 489–92CrossRefGoogle Scholar
  43. 43.
    Denham J, Denham E, Dear K, et al. The follicular non-Hodgkin’s lymphomas, II. Prognostic factors: what do they mean? Eur J Cancer 1996; 32A: 480–90PubMedCrossRefGoogle Scholar
  44. 44.
    Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III–IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients. A study of the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1999; 17: 2499–505PubMedGoogle Scholar
  45. 45.
    Federico M, Vitolo U, Zinzani P, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysisof 987 cases. Blood 2000; 95: 783–9PubMedGoogle Scholar
  46. 46.
    Maartense E, Le Cessie S, Kluin-Nelemans H, et al. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin’s lymphoma registry. Ann Oncol 2002; 13: 1275–84PubMedCrossRefGoogle Scholar
  47. 47.
    Lopez-Guillermo A, Monserrat E, Bosch F, et al. Applicability of the International Prognostic Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–6PubMedGoogle Scholar
  48. 48.
    Aviles A. The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol 1994; 12: 2766–70PubMedGoogle Scholar
  49. 49.
    Bastion U, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular patients? J Clin Oncol 1994; 12: 1340–2PubMedGoogle Scholar
  50. 50.
    Hermans J, Krol A, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460–3PubMedGoogle Scholar
  51. 51.
    Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III–IV patients. Ann Oncol 1997; 8 Suppl. 1: S49–52CrossRefGoogle Scholar
  52. 52.
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104: 1258–65PubMedCrossRefGoogle Scholar
  53. 53.
    Formica V, Norman A, Cunningham D, et al. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol 2009; 122: 193–9PubMedCrossRefGoogle Scholar
  54. 54.
    Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504–8PubMedCrossRefGoogle Scholar
  55. 55.
    Federico M, Bellei M, Marcheselli L, et al. Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor project. J Clin Oncol 2009; 27: 4555–62PubMedCrossRefGoogle Scholar
  56. 56.
    Terol M, Teruel A, Amat P, et al. The FLIPI2 score predicts progression-free survival (PFS) and overall survival (OS) in an independent series of follicular lymphoma: a single institution experience [abstract no. 3128]. Blood 2010; 116: 1288Google Scholar
  57. 57.
    Numata A, Fujimaki K, Tomita N, et al. Retrospective study of the utility of Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 in patients with follicular lymphoma uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [abstract no. 3100]. Blood 2010; 116: 1278Google Scholar
  58. 58.
    Rummel M. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. J Natl Compr Canc Netw 2010; 8: S1–S14PubMedGoogle Scholar
  59. 59.
    Perea G, Altes A, Montoto S, et al. Prognostic indices in follicular lymphoma: a comparison of different prognostic scoring systems. Ann Oncol 2005; 16: 1508–13PubMedCrossRefGoogle Scholar
  60. 60.
    Gine E, Montoto S, Bosch F, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17: 1539–45PubMedCrossRefGoogle Scholar
  61. 61.
    Friedberg J, Taylor M, Cerhan J, et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol 2009; 27: 1202–8PubMedCrossRefGoogle Scholar
  62. 62.
    Gallagher C, Gregory W, Jones A, et al. Follicular lymphomas: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–80PubMedGoogle Scholar
  63. 63.
    Shustik J, Quinn M, Connors J, et al. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 2011; 22: 1164–9PubMedCrossRefGoogle Scholar
  64. 64.
    Hans C, Weisenburger D, Vose J, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363–7CrossRefGoogle Scholar
  65. 65.
    Ganti A, Weisenburger D, Smith L, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience. Ann Oncol 2006; 17: 920–7PubMedCrossRefGoogle Scholar
  66. 66.
    Bartlett N, Rizeq M, Dorfman R, et al. Follicular large-cell lymphoma: intermediate or low-grade? J Clin Oncol 1994; 12: 1349–57PubMedGoogle Scholar
  67. 67.
    Rodriguez J, McLaughlin P, Hagemeister F, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2002–7Google Scholar
  68. 68.
    Wendum D, Sebban C, Gaulard P, et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. J Clin Oncol 1997; 15: 1654–63PubMedGoogle Scholar
  69. 69.
    Bierman P. Natural history of follicular grade 3 non-Hodgkin’s lymphoma. Curr Opin Oncol 2007; 19: 433–7PubMedCrossRefGoogle Scholar
  70. 70.
    Chau I, Jones R, Cunningham D, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89: 36–42PubMedCrossRefGoogle Scholar
  71. 71.
    Miller T, Grogan T, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460–6PubMedGoogle Scholar
  72. 72.
    Frost M, Newell J, Lones M, et al. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384–90PubMedCrossRefGoogle Scholar
  73. 73.
    Thorns C, Kalies K, Fischer U, et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology 2007; 50: 716–9PubMedCrossRefGoogle Scholar
  74. 74.
    Naresh K. MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007; 92: 267–8PubMedCrossRefGoogle Scholar
  75. 75.
    Llanos M, Alvarez-Arguelles H, Aleman R, et al. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001; 18: 15–22PubMedCrossRefGoogle Scholar
  76. 76.
    Broyde A, Boycov O, Strenov Y, et al. Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphoma. Am J Hemotol 2009; 84: 338–43CrossRefGoogle Scholar
  77. 77.
    Salto B, Shiozawa E, Yamochi-Onizuka T, et al. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathol Int 2004; 54: 667–74CrossRefGoogle Scholar
  78. 78.
    Wang S, Wang L, Hochberg E, et al. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005; 29: 1490–6PubMedCrossRefGoogle Scholar
  79. 79.
    Glas A, Kersten M, Delahaye L, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301–7PubMedCrossRefGoogle Scholar
  80. 80.
    Michaels J, Foria V, Mead B, et al. Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 2006; 132: 743–6CrossRefGoogle Scholar
  81. 81.
    Zhao W, Daneshpouy M, Mounier N, et al. Prognostic significance of bcl-cL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004; 103: 695–7PubMedCrossRefGoogle Scholar
  82. 82.
    Gulmann C, Espina V, Petricoin E, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors infollicular lymphoma. Clin Cancer Res 2005; 11: 5847–55PubMedCrossRefGoogle Scholar
  83. 83.
    Torlakovic E, Bilalovic N, Golouh R, et al. Prognostic significance of PU.1 in follicular lymphoma. J Pathol 2006; 209: 352–9PubMedCrossRefGoogle Scholar
  84. 84.
    O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008; 112: 3126–9PubMedCrossRefGoogle Scholar
  85. 85.
    Bjorck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005; 105: 2908–15PubMedCrossRefGoogle Scholar
  86. 86.
    Krishnadasan R, Bifulco C, Kim J, et al. Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. Brit J Haematol 2006; 135: 72–5CrossRefGoogle Scholar
  87. 87.
    Koster A, van Krieken J, Mackenzie M, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154–61PubMedGoogle Scholar
  88. 88.
    Farinha P, Masouldi H, Skinnider B, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–74PubMedCrossRefGoogle Scholar
  89. 89.
    Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440–6PubMedCrossRefGoogle Scholar
  90. 90.
    Wahlin B, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16: 637–50PubMedCrossRefGoogle Scholar
  91. 91.
    Dave S, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–69PubMedCrossRefGoogle Scholar
  92. 92.
    Sakhinia E, Glennie C, Hoyland J, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109: 3922–8PubMedCrossRefGoogle Scholar
  93. 93.
    Glas A, Knoops L, Delahaye L, et al. Gene-expression and immuno-histochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosisoffollicular lymphoma. JClin Oncol 2007; 25: 390–8CrossRefGoogle Scholar
  94. 94.
    Alvaro T, Lejeune M, Camacho F, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91: 1605–12PubMedGoogle Scholar
  95. 95.
    Taskinen M, Karjalainen-Lindsberg M, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784–9PubMedCrossRefGoogle Scholar
  96. 96.
    Alvaro T, Lejeune M, Salvado M, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350–7PubMedCrossRefGoogle Scholar
  97. 97.
    Farinha P, Campo E, Banham A, et al. The architectural pattern of FOXP3+ T cells is an independent predictor of survival in patients with follicular lymphoma (FL) [abstract]. Mod Pathol 2006; 19: 1043aGoogle Scholar
  98. 98.
    Farinha P, Han J, Al-Tourah A, et al. The tumor microenvironment measured by flow cytometry predicts overall survival and transformation risk in follicular lymphoma [abstract no. 2406]. Blood 2006; 108Google Scholar
  99. 99.
    Ai W, Czerwinski D, Horning S, et al. Tumor-infiltrating T cells are not predictive of clinical outcome in follicular lymphoma [abstract no. 824]. Blood 2006; 108Google Scholar
  100. 100.
    Lee A, Clear A, Calaminici M, et al. Number of CD 4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052–9PubMedCrossRefGoogle Scholar
  101. 101.
    Carreras J, Lopez-Guillermo A, Fox B, et al. High numbers of tumorinfiltrating FOXP-3 regulatory T cells are associated with improved survival in follicular lymphoma. Blood 2006; 108: 2957–64PubMedCrossRefGoogle Scholar
  102. 102.
    Strickler J, Copenhaver C, Rojas V, et al. Comparison of host cell infiltrates: in patients with follicular lymphoma with and without spontaneous regression. Am J Clin Pathol 1988; 90: 257–61PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.MD Anderson Cancer CenterHoustonUSA

Personalised recommendations